间充质干细胞应用于类风湿关节炎组织修复的研究进展

doi:10.3969/j.issn.1007-9572.2016.32.024

摘要/Abstract

摘要： 类风湿关节炎（RA）是以滑膜炎及其所致的关节损伤为特征的自身免疫性疾病，现有的治疗方法多是通过药物抑制滑膜炎，而修复关节破坏的疗效甚微。由于间充质干细胞（MSC）是一类具有免疫调节作用，兼具多向分化潜能的干细胞，因此研究者希望通过其在抑制关节炎的同时，修复关节损伤。目前已有将MSC用于RA患者或动物模型治疗的研究报道，但研究结果存在分歧，且关于改善关节破坏的研究相对较少。本文主要总结MSC在RA组织修复中的研究进展，为临床治疗提供参考。

关键词: 关节炎, 类风湿, 间质干细胞, 炎症, 关节软骨修复, 综述

Abstract: Rheumatoid arthritis（RA） is an autoimmune disease characterized by synovitis and articular injury due to synovitis.The current available treatments for RA mainly control synovitis,but have little effects on articular destruction repair.Mesenchymal stem cells（MSC） have effects on immunological regulation,and have the ability of multiple differentiation potential,so MSC have the potential to control synovitis and repair articular destruction.Until now,some researchers have reported the application of MSC in the treatment of RA patients or RA animal models,while these studies lead to different conclusions,and few studies focused on the effects of articular destruction.The studies on application of MSC in the tissue repair of RA are summarized in this article,which may provide the reference for clinical treatment.

Key words: Arthritis,rheumatoid, Mesenchymal stem cells, Inflammation, Articular cartilage repair, Review

张香梅, 田中良哉, 单保恩. 间充质干细胞应用于类风湿关节炎组织修复的研究进展[J]. 中国全科医学, 2016, 19(32): 4014-4018.

ZHANG Xiang-mei, TANAKA Yoshiya, SHAN Bao-en. Research Prognosis of Application of Mesenchymal Stem Cells in the Tissue Repair of Rheumatoid Arthritis[J]. Chinese General Practice, 2016, 19(32): 4014-4018.

参考文献

［1］SMOLEN J S,ALETAHA D.Rheumatoid arthritis therapy reappraisal:strategies,opportunities and challenges［J］.Nat Rev Rheumatol,2015,11（5）:276-289. ［2］MCINNES I B,BUCKLEY C D,ISAACS J D.Cytokines in rheumatoid arthritis - shaping the immunological landscape［J］.Nat Rev Rheumatol,2016,12（1）:63-68. ［3］TANAKA Y.Current concepts in the management of rheumatoid arthritis［J］.Korean J Intern Med,2016,31（2）:210-218. ［4］BOTTINI N,FIRESTEIN G S.Duality of fibroblast-like synoviocytes in RA:passive responders and imprinted aggressors［J］.Nat Rev Rheumatol,2013,9（1）:24-33. ［5］LEFVRE S,KNEDLA A,TENNIE C,et al.Synovial fibroblasts spread rheumatoid arthritis to unaffected joints［J］.Nat Med,2009,15（12）:1414-1420. ［6］BARTOK B,FRIESTEIN G S.Fibroblast-like synoviocytes:key effector cells in rheumatoid arthritis［J］.Immunol Rev,2010,233（1）:233-255. ［7］FRIESTEIN G S.Evolving concepts of rheumatoid arthritis［J］.Nature,2003,423（6937）:356-361. ［8］MCINNES I B,SCHETT G.Cytokines in the pathogenesis of rheumatoid arthritis［J］.Nat Rev Immunol,2007,7（6）:429-442. ［9］PITTENGER M F,MACKAY A M,BECK S C,et al.Multilineage potential of adult human mesenchymal stem cells［J］.Science,1999,284（5411）:143-147. ［10］UCCELLI A,MORETTA L,PISTOIA V.Mesenchymal stem cells in health and disease［J］.Nat Rev Immunol,2008,8（9）:726-736. ［11］REISSIS D,TANG Q O,COOPER N C,et al.Current clinical evidence for the use of mesenchymal stem cells in articular cartilage repair［J］.Expert Opin Biol Ther,2016,16（4）:535-557. ［12］MACDONALD G I,AUGELLO A,DE BARI C.Role of mesenchymal stem cells in reestablishing immunologic tolerance in autoimmune rheumatic diseases［J］.Arthritis Rheum,2011,63（9）:2547-2557. ［13］LE BLANC K,RASMUSSON I,SUNDBERG B,et al.Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells［J］.Lancet,2004,363（9419）:1439-1441. ［14］SUN L,AKIYAMA K,ZHANG H,et al.Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans［J］.Stem Cells,2009,27（6）:1421-1432. ［15］LIANG J,ZHANG H,HUA B,et al.Allogeneic mesenchymal stem cells transplantation in treatment of multiple sclerosis［J］.Mult Scler,2009,15（5）:644-646. ［16］TANAKA Y.Human mesenchymal stem cells as a tool for joint repair in rheumatoid arthritis［J］.Clin Exp Rheumatol,2015,33（4 Suppl 92）:S58-62. ［17］DE BARI C.Are mesenchymal stem cells in rheumatoid arthritis the good or bad guys［J］.Arthritis Res Ther,2015,17:113. ［18］DJOUAD F,FRITZ V,APPARAILLY F,et al.Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis［J］.Arthritis Rheum,2005,52（5）:1595-1603. ［19］AUGELLO A,TASSO R,NEGRINI S M,et al.Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis［J］.Arthritis Rheum,2007,56（4）:1175-1186. ［20］GONZLEZ M A,GONZALEZ-REY E,RICO L,et al.Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells［J］.Arthritis Rheum,2009,60（4）:1006-1019. ［21］SCHURGERS E,KELCHTERMANS H,MITERA T,et al.Discrepancy between the in vitro and in vivo effects of murine mesenchymal stem cells on T-cell proliferation and collageninduced arthritis［J］.Arthritis Res Ther,2010,12（1）:R31. ［22］PARK M J,PARK H S,CHO M L,et al.Transforming growth factor-beta transduced mesenchymal stem cells ameliorate autoimmune arthritis through reciprocal regulation of Treg/Th17 cells and osteoclastogenesis［J］.Arthritis Rheum,2011,63（6）:1668-1680. ［23］LIU Y,MU R,WANG S,et al.Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis［J］.Arthritis Res Ther,2010,12（6）:R210. ［24］BOUFFI C,BONY C,COURTIES G,et al.IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis［J］.PLoS One,2010,5（12）:e14247. ［25］CHOI J J,YOO S A,PARK S J,et al.Mesenchymal stem cells overexpressing interleukin-10 attenuate collagen-induced arthritis in mice［J］.Clin Exp Immunol,2008,153（2）:269-276. ［26］CHEN B,HU J,LIAO L,et al.Flk-1+mesenchymal stem cells aggravate collagen-induced arthritis byup-regulating interleukin-6［J］.Clin Exp Immunol,2010,159（3）:292-302. ［27］王黎明,周建军,白雯,等.脐带间充质干细胞治疗17例类风湿性关节炎患者的临床疗效观察［J］.中国免疫学杂志,2010,26（7）:659-662. WANG L M,ZHOU J J,BAI W,et al.Therapeutic efficacy of umbilical cord mesenchymal stem cells for rheumatoid arthritis in seventeen patients［J］.Chinese Journal of Immunology,2010,26（7）:659-662. ［28］LIANG J,LI X,ZHANG H,et al.Allogeneic mesenchymal stem cells transplantation in patients with refractory RA［J］.Clin Rheumatol,2012,31（1）:157-161. ［29］RINGE J,BURMESTER G R,SITTINGER M.Regenerative medicine in rheumatic disease-progress in tissue engineering［J］.Nat Rev Rheumatol,2012,8（8）:493-498. ［30］李慧,顾健,林传明,等.脐带间充质干细胞对CIA大鼠炎症因子的干预［J］.中国组织工程研究与临床康复,2011,15（36）:6701-6704. LI H,GU J,LIN C M,et al.Umbilical cord mesenchymal stem cells effect on inflammatory responses of rats with type Ⅱ collagen-induced arthritis［J］.Journal of Clinical Rehabilitative Tissue Engineering Research,2011,15（36）:6701-6704. ［31］TANAKA Y,SONOMOTO K,KONDO M,et al.Mesenchymal stem cells for the treatment and repair of inflammatory arthritis［J］.Nihon Rinsho Meneki Gakkai Kaishi,2015,38（2）:86-92. ［32］MAGNE D,VINATIER C,JULIEN M,et al.Mesenchymal stem cell therapy to rebuild cartilage［J］.Trends Mol Med,2005,11（11）:519-526. ［33］KONDO M,YAMAOKA K,TANAKA Y.Acquiring chondrocyte phenotype from human mesenchymal stem cells under inflammatory conditions［J］.Int J Mol Sci,2014,15（11）:21270-21285. ［34］ZHENG Z H,LI X Y,DING J,et al.Allogeneic mesenchymal stem cell and mesenchymal stem cell-differentiated chondrocyte suppress the responses of typeⅡ collagen-reactive T cells in rheumatoid arthritis［J］.Rheumatology（Oxford）,2008,47（1）:22-30. ［35］SONOMOTO K,YAMAOKA K,OSHITA K,et al.Interleukin-1β induces differentiation of human mesenchymal stem cells into osteoblasts via the Wnt-5a/receptor tyrosine kinase-like orphan receptor 2 pathway［J］.Arthritis Rheum,2012,64（10）：3355-3363. ［36］KONDO M,YAMAOKA K,SAKATA K,et al.Contribution of the Interleukin-6/STAT-3 signaling pathway to chondrogenic differentiation of human mesenchymal stem cells［J］.Arthritis Rheumatol,2015,67（5）:1250-1260. ［37］OSHITA K,YAMAOKA K,UDAGAWA N,et al.Human mesenchymal stem cells inhibit osteoclastogenesis through osteoprotegerin production［J］.Arthritis Rheum,2011,63（6）:1658-1667. ［38］GHANNAM S,BOUFFI C,DJOUAD F,et al.Immunosuppression by mesenchymal stem cells:mechanisms and clinical applications［J］.Stem Cell Res Ther,2010,1（1）:2. ［39］CHAMBERLAIN G,FOX J,ASHTON B,et al.Concise review:mesenchymal stem cells:their phenotype,differentiation capacity,immunological features,and potential for homing［J］.Stem Cells,2007,25（11）:2739-2749. ［40］ROMBOUTS W J,PLOEMACHER R E.Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture［J］.Leukemia,2003,17（1）:160-170. ［41］SMITH D M,SINON J K,BAKER J R Jr.Applications of nanotechnology for immunology［J］.Nat Rev Immunol,2013,13（8）:592-605. ［42］SONOMOTO K,YAMAOKA K,TANAKA Y.An approach to bone and cartilage repair of rheumatoid arthritis by mesenchymal stem cells［J］.J UOEH,2014,36（2）:141-146. ［43］L J M,WANG X,MARIN-MULLER C,et al.Current advances in research and clinical applications of PLGA-based nanotechnology［J］.Expert Rev Mol Diagn,2009,9（4）:325-341. ［44］DAVIES J E,MATTA R,MENDES V C,et al.Development,characterization and clinical use of a biodegradable composite scaffold for bone engineering in oro-maxillo-facial surgery［J］.Organogensis,2010,6（3）:161-166. ［45］ZHANG X,YAMAOKA K,SONOMOTO K,et al.Local delivery of mesenchymal stem cells with poly-lactic-co-glycolic acid nano-fiber scaffold suppress arthritis in rats［J］.PLoS One,2014,9（12）:e114621. ［46］KOIZUMI K,EBINA K,HART D A,et al.Synovial mesenchymal stem cells from osteo-or rheumatoid arthritis joints exhibit good potential for cartilage repair using a scaffold-free tissue engineering approach［J］.Osteoarthritis Cartilage,2016,24（8）:1413-1422. ［47］PAPADOPULOU A,YIANGOU M,ATHANASIOU E,et al.Mesenchymal stem cells are conditionally therapeutic in preclinical models of rheumatoid arthritis［J］.Ann Rheum Dis,2012,71（10）:1733-1740. ［48］BOLON B,STOLINA M,KING C,et al.Rodent preclinical models for developing novel antiarthritic molecules:comparative biology and preferred methods for evaluating efficacy［J］.J Biomed Biotechnol,2001,2011:569068. ［49］STEINBERG M E,MCRAE C R,BERSELLI R A,et al.Intra-articular 5-fluorouracil in antigen-induced arthritis［J］.J Bone Joint Surg Am,1971,53（3）:514-522. ［50］LIU H,DING J,WANG C,et al.Intra-articular transplantation of allogeneic BMMSCs rehabilitates cartilage injury of antigen-induced arthritis［J］.Tissue Eng Part A,2015,21（21/22）:2733-2743. ［51］KEHOE O,CARTWRIGHT A,ASKARI A,et al.Intra-articular injection of mesenchymal stem cells leads to reduced inflammation and cartilage damage in murine antigen-inducedarthritis［J］.J Transl Med,2014,12:157. ［52］LIU P,SUN L,CHEN H,et al.Lentiviral-mediated multiple gene transfer to chondrocytes promotes chondrocyte differentiation and bone formation in rabbit bone marrow-derived mesenchymal stem cells［J］.Oncol Rep,2015,34（5）:2618-2626. ［53］GELSE K,VON DER MARK K,AIGNER T,et al.Articular cartilage repair by gene therapy using growth factor-producing mesenchymal cells［J］.Arthritis Rheum,2003,48（2）:430-441.

[1]	项天乐, 周娜, 李芳, 曹梅娟. 儿童24 h活动行为测评方法研究进展[J]. 中国全科医学, 2026, 29(06): 760-766.
[2]	王立娜, 雷警输, 李奎宝, 王睿颖, 李新苗, 王芳芳, 郭晓荣, 牛瑞浩, 赵伟, 周芳芳, 赵京晶, 李忠佑. 急性心肌梗死患者炎症反应研究进展[J]. 中国全科医学, 2026, 29(06): 790-801.
[3]	史佳琦, 王玉欣, 罗佳妮, 姜琪, 吴善玉, 金头峰. 胃肠道癌症患者症状群影响因素的范围综述[J]. 中国全科医学, 2026, 29(05): 668-675.
[4]	田紫薇, 杨支兰, 赵慧敏, 翟艳萍, 李鸿雁, 杜淼, 晋源媛, 宋泽雨. 膝骨关节炎患者衰弱研究的范围综述[J]. 中国全科医学, 2026, 29(05): 676-680.
[5]	曹新阳, 汪洋, 金花, 于德华, 杨辉, 刘晓云, 许岩丽. 全科医学科研能力发展的影响因素：一项范围综述[J]. 中国全科医学, 2026, 29(04): 444-456.
[6]	王艺衡, 许晓明, 夏云龙, 夏林莺, 韩雪, 郭永珍, 刘泉池, 闫文俊. 射血分数保留的心力衰竭药物治疗进展[J]. 中国全科医学, 2026, 29(03): 403-408.
[7]	刘燕, 袁艳玲, 令榕, 王兰云, 孙丽. 远程医疗在冠心病患者心脏康复中应用的范围综述[J]. 中国全科医学, 2025, 28(36): 4640-4647.
[8]	王怡, 程金湘, 赵显超, 任佳封, 张丽萍, 董孟龙, 林志烽, 宿长军. 药物相关的快速眼动睡眠行为障碍研究新进展[J]. 中国全科医学, 2025, 28(35): 4511-4516.
[9]	陈荟雨, 徐紫燕, 李玉红. 孕晚期女性膳食炎症指数和泌乳启动延迟的相关性研究[J]. 中国全科医学, 2025, 28(35): 4442-4448.
[10]	倪明珠, 王莉, 许珍晶, 石桥, 侯志峰. Wilson病合并轻度认知障碍患者血清晚期糖基化终产物受体/核因子κB通路关键分子表达水平变化及其与认知功能关系的研究[J]. 中国全科医学, 2025, 28(35): 4430-4434.
[11]	李明月, 汤皓晴, 郑汇娴, 张笑天, 刘晓云. 基本卫生保健质量概念内涵研究的系统综述[J]. 中国全科医学, 2025, 28(34): 4300-4310.
[12]	王梦奇, 梁墨瑄, 李泽远, 郭玉婷, 程景民. 间歇性禁食对2型糖尿病患者应用效果的范围综述[J]. 中国全科医学, 2025, 28(33): 4234-4240.
[13]	王碧优, 高鹰, 尤俊方, 刘莉, 张卿, 苏海燕. 心血管疾病风险人群脂质比值与炎症指标的典型相关性研究[J]. 中国全科医学, 2025, 28(33): 4132-4139.
[14]	高佳新, 周蕊寒, 王芳芳, 庞日朝, 张安仁. 饮食限制对机体免疫功能调节作用的研究进展[J]. 中国全科医学, 2025, 28(32): 4102-4109.
[15]	张曦, 管成果, 王婧, 许丁昕, 张博. 痴呆症患者预立医疗照护计划干预策略的研究新进展[J]. 中国全科医学, 2025, 28(32): 4109-4116.